Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring
JAC-Antimicrobial Resistance · 02.07.2026 · 8 (4)
DOI: 10.1093/jacamr/dlag150 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 24.07.2026. Verfasst von Simone Giuliano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Division, Department of Medicine (DMED), University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, …. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Oritavancin is a long-acting semisynthetic lipoglycopeptide with potent activity against a broad range of Gram-positive pathogens. Its multimodal mechanism of action and prolonged terminal half-life allow for extended dosing intervals, making it an off-label option for invasive infections requiring long-term antimicrobial exposure. However, evidence supporting its use in infective endocarditis and cardiac device–related infections remain limited.
Methods
We performed a retrospective multicentre observational study including adult patients treated with multidose oritavancin for infective endocarditis and cardiac device-related infections between 2020 and 2025. Oritavancin was administered as consolidation or as long-term suppressive therapy. Demographic, clinical, microbiological, pharmacological, and outcome data were collected. Therapeutic drug monitoring was performed, and pre-dose plasma concentrations were analysed. Clinical outcomes included clinical cure, microbiological failure, adverse events, and 30- and 90-day all-cause mortality.
Results
Nine patients were included. Oritavancin was mainly administered at 1200 mg per dose, with a median dosing interval of 10 days. Clinical success was achieved in 6/9 patients (66.7%). One patient discontinued therapy due to infusion-related adverse events, and two experienced microbiological failure, both in left ventricular assist device-related infections. No 30- or 90-day mortality was observed. TDM, when performed, demonstrated persistent pre-dose plasma concentrations over several weeks, with marked interindividual variability across patients and intra-individual temporal changes over time, including drug accumulation in some cases.
Conclusion
Multidose oritavancin appears to be a promising consolidation or suppressive strategy in selected patients with complex Gram-positive endovascular infections. Prospective studies are needed to define optimal dosing regimens and the role of TDM in this setting.
Autor:innen und Institutionen
- Infectious Diseases Division, Department of Medicine (DMED), University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.
- Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano Hospital, Lugano, Switzerland.
- Clinical Pharmacology and Toxicology Institute, University Hospital Friuli Centrale ASUFC, Udine 33100, Italy.
- Department of Medicine (DMED), University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.
- Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin-ASL 'Città di Torino', Turin, Italy.
- Department of Diagnostic and Public Health, University of Verona, Verona, Italy.
ORCID-Profile: Luca Martini, Maria Merelli, Paolo Gaibani, Marco Bongiovanni, Carlo Tascini
Zitieren
APA
Giuliano, S., Martini, L., Merelli, M., Turicchi, G., Angelini, J., Ferin, S., D'avolio, A., Gaibani, P., Bongiovanni, M., & Tascini, C. (2026). Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring. JAC-Antimicrobial Resistance, 8(4). https://doi.org/10.1093/jacamr/dlag150
Vancouver
Giuliano S, Martini L, Merelli M, Turicchi G, Angelini J, Ferin S, et al. Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring. JAC-Antimicrobial Resistance. 2026;8(4). doi:10.1093/jacamr/dlag150
BibTeX
@article{Giuliano2026,
author = {Giuliano, Simone and Martini, Luca and Merelli, Maria and Turicchi, Giulia and Angelini, Jacopo and Ferin, Sara and D'avolio, Antonio and Gaibani, Paolo and Bongiovanni, Marco and Tascini, Carlo},
title = {Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring},
journal = {JAC-Antimicrobial Resistance},
year = {2026},
volume = {8},
number = {4},
doi = {10.1093/jacamr/dlag150}
}
EUVIMED